Clinuvel Pharmaceuticals (FRA:UR9) Total Receivables : €8.03 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Receivables?

Clinuvel Pharmaceuticals's Total Receivables for the quarter that ended in Dec. 2023 was €8.03 Mil.

Clinuvel Pharmaceuticals Total Receivables Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Receivables Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Receivables

Get a 7-Day Free Trial

2.55

4.05

10.21

10.77

13.76

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Receivables	Get a 7-Day Free Trial															6.39	10.77	6.79	13.76	8.03

Clinuvel Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Clinuvel Pharmaceuticals Total Receivables Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (FRA:UR9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (FRA:UR9) Headlines

No Headlines